SeaStar Medical Holding Corp (ICU) Stock Analysis

Verdict: AVOID

Commercial momentum for QUELIMMUNE is building, but an acute cash runway of under 7 months makes severe equity dilution almost inevitable.

Investment score: 35/100

Analysis as of

Is SeaStar Medical Holding Corp stock worth reviewing? The TradeMates thesis

The TradeMates model assigns ICU an AVOID rating due to imminent balance sheet dilution risks despite early revenue traction for QUELIMMUNE.

7-factor investment score

SeaStar Medical Holding Corp opportunities and risks

What speaks for ICU

What speaks against ICU

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
ICUn/a5.9xn/a92.6%-795.5%-134.8%
RDGLn/a243.2xn/a-344.1%-3633.3%-10.3%
BEATn/a0.0xn/a0.0%0.0%-63.7%
PAVMn/a149.9xn/a-254.5%-10794.6%-15637.4%
GTHPn/a28.2xn/a64.0%-573.1%-8.2%
Peer mediann/a89.1xn/a-127.2%-2103.2%-37.0%

Frequently asked questions about SeaStar Medical Holding Corp (ICU)

Is ICU stock a good investment?

The TradeMates model rates SeaStar Medical Holding Corp as AVOID with an investment score of 35/100. The TradeMates model assigns ICU an AVOID rating due to imminent balance sheet dilution risks despite early revenue traction for QUELIMMUNE. This is algorithmic model output, not personal investment advice.

Is ICU stock a buy?

The TradeMates model verdict for ICU is AVOID with an investment score of 35/100. Treat this as a model signal to review, not a personal buy recommendation.